Orexigen Therapeutics, Inc. develops drug treatments for obesity and related disorders. Orexigen Therapeutics, Inc. develops and commercializes combinations of currently available drugs that are designed to achieve and sustain weight loss by enhancing satiety, diminishing appetite, improving energy expenditure and minimizing the body's efforts to compensate for weight loss.
|Headquarters||Suite 200, 3344 N. Torrey Pines Court|
LA JOLLA, CA, United States 92037
|Independent Chairman of the Board||Eckard Weber|
|President, Chief Executive Officer, Director||Michael Narachi|
|Acting Chief Financial Officer, Treasurer, Chief Business Officer||Joseph Hagan|
|Senior Vice President, General Counsel, Secretary||Heather Turner|
|Head of Global Contrave Program, Senior Vice President - Product Development||Preston Klassen|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
|Shares Out.||94.6M||Book Value||$0.89|
|Annual Dividend Rate||$0.00||Price/Sales (TTM)||166.2|
|Ex-Div Date||1/1/01||P/Cash Flow (TTM)||--|
|Pay Date||1/1/01||Operating Margin||-2,893.29%|
*GAAP = prior to non-GAAP analyst adjusted earnings.